Thursday, March 30, 2023
Thermo Fisher Scientific and Arsenal Biosciences announced an update to the strategic collaboration to further the development of manufacturing processes for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
By partnering with ArsenalBio as a pioneer in T-cell therapy for solid tumours, helps to provide more options who are most in need of innovative treatments. This collaborative cell therapy programme, enables the industry to move from reactive to proactive, leverage biological and technical expertise to improve the economics of therapeutic production, and move towards expanded access to patients worldwide.
This partnership with Thermo Fisher allows to combine targeted solutions and expertise with the team's innovative approach to clinical trials and processing capabilities to manufacture ArsenalBio products and explore future therapeutic innovations.
